Alterity Therapeutics (ASX:ATH) has been granted authorisation to conduct a Phase 2 clinical trial for ATH434, an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration, in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.

The trial will enroll approximately 60 adults, who will receive one of two dose levels of ATH434 or placebo treatment for 12 months, and will evaluate the effect of ATH434 on neuroimaging and protein biomarkers, as well as assessments of safety and pharmacokinetics.

The study is expected to open trial sites in France and Austria over the next few months.

Alterity Therapeutics says ATH434 has been granted Orphan designation for the treatment of MSA by the U.S. FDA and the European Commission.